Pages that link to "Q88117871"
Jump to navigation
Jump to search
The following pages link to Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial (Q88117871):
Displaying 50 items.
- Options for empagliflozin in combination therapy in type 2 diabetes mellitus (Q26745771) (← links)
- The Association between Sulfonylurea Use and All-Cause and Cardiovascular Mortality: A Meta-Analysis with Trial Sequential Analysis of Randomized Clinical Trials (Q26748870) (← links)
- Differential pharmacology and clinical utility of empagliflozin in type 2 diabetes (Q26749281) (← links)
- Empagliflozin (Q26773311) (← links)
- Spotlight on empagliflozin/metformin fixed-dose combination for the treatment of type 2 diabetes: a systematic review (Q28071386) (← links)
- Impact of sodium-glucose cotransporter 2 inhibitors on blood pressure (Q28080114) (← links)
- The Use of SGLT-2 Inhibitors in Type 2 Diabetes and Heart Failure (Q28082343) (← links)
- Comparative efficacy and safety of antidiabetic drug regimens added to metformin monotherapy in patients with type 2 diabetes: a network meta-analysis (Q28546797) (← links)
- Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis (Q28553482) (← links)
- Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus (Q30249371) (← links)
- Effects of sodium-glucose co-transporter 2 (SGLT2) inhibition on renal function and albuminuria in patients with type 2 diabetes: a systematic review and meta-analysis (Q32186373) (← links)
- Addition of Ipragliflozin to Metformin Treatment in Korean Patients with Type 2 Diabetes Mellitus: Subgroup Analysis of a Phase 3 Trial (Q33614337) (← links)
- Impact of Sodium-Glucose Cotransporter 2 Inhibitors on Nonglycemic Outcomes in Patients with Type 2 Diabetes (Q33625568) (← links)
- Long-term efficacy and safety of sodium-glucose cotransporter-2 inhibitors as add-on to metformin treatment in the management of type 2 diabetes mellitus: A meta-analysis (Q33885732) (← links)
- Empagliflozin in the treatment of type 2 diabetes: evidence to date (Q34502358) (← links)
- Sodium-glucose co-transporter 2 (SGLT2) inhibitors: a growing class of antidiabetic agents (Q34973750) (← links)
- Effect of empagliflozin monotherapy on postprandial glucose and 24-hour glucose variability in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, 4-week study (Q35117192) (← links)
- SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials (Q35181821) (← links)
- Short commentary on empagliflozin and its potential clinical impact (Q35528797) (← links)
- Efficacy and safety of empagliflozin as add-on to metformin for type 2 diabetes: a systematic review and meta-analysis (Q35911236) (← links)
- Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis. (Q35968414) (← links)
- A post-hoc analysis of the comparative efficacy of canagliflozin and glimepiride in the attainment of type 2 diabetes-related quality measures (Q36096350) (← links)
- Comparison of Adipose Distribution Indices with Gold Standard Body Composition Assessments in the EMPA-REG H2H SU Trial: A Body Composition Sub-Study (Q36360090) (← links)
- Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naïve patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial (Q36402095) (← links)
- Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4-week, randomized, placebo-controlled trial (EASE-1) (Q36555418) (← links)
- The potential role of sodium glucose co-transporter 2 inhibitors in the early treatment of type 2 diabetes mellitus (Q36592820) (← links)
- Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus (Q36622125) (← links)
- Treatment satisfaction in type 2 diabetes patients taking empagliflozin compared with patients taking glimepiride (Q36823710) (← links)
- A Safety Evaluation of Empagliflozin for the Treatment of Type 2 Diabetes (Q36960633) (← links)
- Simultaneous Reduction in Both HbA1c and Body Weight with Canagliflozin Versus Glimepiride in Patients with Type 2 Diabetes on Metformin (Q36989681) (← links)
- Empagliflozin/linagliptin single-tablet combination: first-in-class treatment option (Q37308941) (← links)
- Impact of the 8-week Administration of Tofogliflozin for Glycemic Control and Body Composition in Japanese Patients with Type 2 Diabetes Mellitus (Q37521103) (← links)
- Safe and pragmatic use of sodium-glucose co-transporter 2 inhibitors in type 2 diabetes mellitus: South Asian Federation of Endocrine Societies consensus statement (Q37588847) (← links)
- Luseogliflozin reduces epicardial fat accumulation in patients with type 2 diabetes: a pilot study (Q37679243) (← links)
- Long-Term Efficacy and Safety of Empagliflozin Monotherapy in Drug-Naïve Patients with Type 2 Diabetes in Indian Subgroup: Results from a 76-week Extension Trial of Phase III, Double-Blind, Randomized Study (Q37721942) (← links)
- Empagliflozin: a review of its use in patients with type 2 diabetes mellitus (Q38255999) (← links)
- Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus (Q38285582) (← links)
- Extra-glycaemic properties of empagliflozin. (Q38494441) (← links)
- Empagliflozin: a sodium-glucose cotransporter 2 inhibitor for treatment of type 2 diabetes (Q38626396) (← links)
- SGLT2 inhibitors and risk of cancer in type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials (Q38654762) (← links)
- The beneficial effects of empagliflozin, an SGLT2 inhibitor, on atherosclerosis in ApoE -/- mice fed a western diet (Q38730067) (← links)
- Sodium-glucose co-transporter 2 inhibitors for type 2 diabetes mellitus: An overview for the primary care physician (Q38821464) (← links)
- Impact of empagliflozin in patients with diabetes and heart failure (Q38822815) (← links)
- Cardiovascular effects of anti-diabetes drugs (Q38857056) (← links)
- SGLT2 inhibitors in the management of type 2 diabetes (Q38857523) (← links)
- Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials (Q38863649) (← links)
- Empagliflozin: Role in Treatment Options for Patients with Type 2 Diabetes Mellitus (Q39006105) (← links)
- Effects of glucose-lowering agents on ischemic stroke (Q39427199) (← links)
- Long-term follow-up of a hospital-based, multi-intervention programme in type 2 diabetes mellitus: impact on cardiovascular events and death (Q40154695) (← links)
- Ipragliflozin Reduces Epicardial Fat Accumulation in Non-Obese Type 2 Diabetic Patients with Visceral Obesity: A Pilot Study (Q41259429) (← links)